Qiagen Shares Surge on Reported Takeover Interest From EQT and Advent
Private equity giants EQT and Advent are said to be eyeing Qiagen, sending shares of the life-sciences firm sharply higher.
Shares of Qiagen climbed sharply after reports emerged that two major private equity firms — EQT and Advent International — have expressed acquisition interest in the Dutch-American life-sciences and diagnostics company. The news injected fresh momentum into a stock that operates in a sector long considered attractive to buyout investors seeking stable, recurring revenue streams from scientific instrumentation and molecular testing products.
Qiagen occupies a distinctive niche in the life-sciences tools market, supplying sample and assay technologies used in everything from clinical diagnostics to pharmaceutical research. That kind of diversified, recurring demand profile is precisely what large-cap private equity acquirers tend to prize — predictable cash flows, defensible market positioning, and meaningful barriers to entry built on proprietary chemistry and instrument ecosystems.
Read more Adobe Stock Jumps 5.6% But Trades Far Below Estimated Fair Value →
The reported interest from EQT and Advent underscores a broader trend: private equity's continued appetite for healthcare and life-sciences assets even as higher interest rates have complicated leveraged buyout economics more broadly. Both firms have deep experience in the sector, and a potential deal for Qiagen — which carries a multi-billion-dollar market capitalization — would rank among the more significant take-private transactions in the diagnostics space in recent years.
For Qiagen's existing shareholders, the speculation raises familiar questions about valuation and strategic fit. The company previously attracted takeover attention from Thermo Fisher Scientific, which abandoned a roughly $11.5 billion bid in 2020 after insufficient shareholder support. That history sets an implicit floor for what investors might expect from any renewed approach, and it also signals that Qiagen's board has not always found outside offers compelling enough to recommend.
Whether EQT, Advent, or both ultimately formalize bids remains uncertain, and reports of early-stage interest frequently do not culminate in signed deals. Still, the market's reaction reflects genuine conviction that Qiagen's assets carry strategic value well beyond its recent trading range. Continue reading at SeekingAlpha.
